INLB logo

Item 9 Labs Corp. (INLB) Análisis de Acciones

Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

INLB representa a Item 9 Labs Corp., una empresa del sector Healthcare con un precio de $ (capitalización de mercado 0). Calificado con 45/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.

Ultimo analisis: 16 mar 2026
Puntuación de IA de 45/100

Item 9 Labs Corp. (INLB) Resumen de Asistencia Médica y Tuberías

CEOJeffrey I. Rassas
Empleados97
Sede CentralPhoenix, US
Año de la oferta pública inicial (OPI)2012

Item 9 Labs Corp. operates as a vertically integrated cannabis company, producing and distributing cannabis products through its dispensaries and franchised Unity Rd locations. Focused on the Arizona market, the company navigates the evolving regulatory landscape of the specialty and generic drug manufacturing sector.

Procedencia de los datos | Datos financieros Análisis cuantitativo NASDAQ Análisis: 16 mar 2026

Tesis de Inversión

Item 9 Labs Corp. presents a unique investment opportunity within the cannabis sector due to its vertically integrated business model and dispensary franchising strategy. The company's focus on the Arizona market, combined with its Unity Rd franchise network, positions it for growth as the cannabis industry matures. However, investors may want to evaluate the risks associated with operating in a highly regulated and competitive market. With a negative P/E ratio and a negative profit margin of -143.1%, the company's profitability is a concern. Key growth catalysts include expansion of the dispensary network and increased brand recognition. The company's gross margin of 33.6% indicates potential for improved profitability with scale. The company's beta of 0.15 suggests low volatility relative to the market.

Basado en las finanzas de FMP y el análisis cuantitativo

Puntos clave

  • Vertically integrated operations provide control over the entire cannabis value chain, from cultivation to retail.
  • Franchise model through Unity Rd offers a scalable approach to expanding dispensary network.
  • Focus on the Arizona market allows for targeted marketing and distribution strategies.
  • Gross margin of 33.6% indicates potential for profitability improvements.
  • Negative profit margin of -143.1% highlights the need for improved cost management and revenue growth.

Competidores y Pares

Fortalezas

  • Vertically integrated operations
  • Franchise model for expansion
  • Established presence in Arizona
  • Diverse product offerings

Debilidades

  • Negative profitability
  • Limited geographic diversification
  • Reliance on a single state market (Arizona)
  • Small market capitalization

Catalizadores

  • Upcoming: Expansion of dispensary network through new openings and franchise growth.
  • Ongoing: Increasing legalization of cannabis in additional states, creating new market opportunities.
  • Ongoing: Product innovation and development of new cannabis-derived products.
  • Upcoming: Potential strategic partnerships or acquisitions to expand market reach.
  • Ongoing: Brand building and marketing efforts to increase brand awareness and customer loyalty.

Riesgos

  • Potential: Regulatory uncertainty and changes in cannabis laws.
  • Ongoing: Intense competition from other cannabis companies.
  • Potential: Fluctuations in cannabis prices and supply.
  • Ongoing: Negative profitability and the need for improved cost management.
  • Potential: Limited access to capital and financing challenges.

Oportunidades de crecimiento

  • Expansion of Dispensary Network: Item 9 Labs Corp. can expand its revenue by opening new dispensaries in Arizona and other states where cannabis is legal. The legal cannabis market is projected to reach $50 billion by 2026, providing a significant growth opportunity for companies with established retail networks. The company's Unity Rd franchise model offers a capital-efficient way to expand its footprint. This expansion could be executed over the next 3-5 years.
  • Product Innovation and Diversification: Item 9 Labs Corp. can drive growth by introducing new cannabis products and expanding its product offerings. The company can focus on developing innovative products that cater to specific consumer needs and preferences. This could include new strains of cannabis, edibles, topicals, and other cannabis-derived products. The timeline for this growth opportunity is immediate and ongoing.
  • Strategic Partnerships and Acquisitions: Item 9 Labs Corp. can accelerate its growth by forming strategic partnerships with other companies in the cannabis industry. This could include partnerships with cultivators, processors, distributors, and retailers. The company can also pursue acquisitions of complementary businesses to expand its product offerings and market reach. The timeline for this growth opportunity is within the next 2-3 years.
  • Brand Building and Marketing: Item 9 Labs Corp. can invest in building its brand and marketing its products to increase brand awareness and customer loyalty. The company can use a variety of marketing channels, including social media, digital advertising, and traditional advertising. The company can also sponsor events and participate in industry trade shows to promote its brand. The timeline for this growth opportunity is immediate and ongoing.
  • Franchise Expansion: Item 9 Labs Corp. can significantly grow its revenue by expanding its Unity Rd franchise network across multiple states. The company can target states with favorable cannabis regulations and a strong demand for cannabis products. This expansion can be achieved through targeted marketing campaigns and by offering attractive franchise terms to potential franchisees. The timeline for this growth opportunity is within the next 3-5 years.

Oportunidades

  • Expansion into new states
  • Product innovation and diversification
  • Strategic partnerships and acquisitions
  • Increasing legalization of cannabis

Amenazas

  • Regulatory uncertainty
  • Intense competition
  • Fluctuations in cannabis prices
  • Changing consumer preferences

Ventajas competitivas

  • Vertically integrated operations provide cost advantages and quality control.
  • Unity Rd franchise network offers a scalable expansion model.
  • Established presence in the Arizona cannabis market.

Acerca de INLB

Item 9 Labs Corp., headquartered in Phoenix, Arizona, is a vertically integrated cannabis operator and dispensary franchisor. The company cultivates, processes, and retails cannabis and cannabis-related products. Its operations span various product categories, including flower, concentrates, distillates, and hardware. Item 9 Labs distributes its products through its own licensed dispensaries and through franchised locations operating under the Unity Rd brand. The company focuses primarily on the Arizona market, catering to both medical and adult-use cannabis consumers. Its business model integrates cultivation, manufacturing, distribution, and retail sales, allowing for greater control over product quality and supply chain efficiency. Item 9 Labs also seeks to expand its footprint through franchising, offering entrepreneurs the opportunity to operate cannabis dispensaries under a recognized brand. The company's vertically integrated approach aims to capture a larger share of the cannabis value chain, from seed to sale. The company's strategy involves expanding its dispensary network and product offerings to meet the growing demand for cannabis products in Arizona and beyond.

Qué hacen

  • Cultivates cannabis plants.
  • Processes cannabis into various products like flower, concentrates, and distillates.
  • Manufactures cannabis-related hardware.
  • Operates licensed cannabis dispensaries in Arizona.
  • Sells medical and adult-use cannabis products.
  • Franchises cannabis dispensaries under the Unity Rd brand.

Modelo de Negocio

  • Vertically integrated operations from cultivation to retail sales.
  • Generates revenue through direct sales at company-owned dispensaries.
  • Earns franchise fees and royalties from Unity Rd franchisees.

Contexto de la Industria

Item 9 Labs Corp. operates within the rapidly evolving cannabis industry, which is characterized by increasing legalization and growing consumer demand. The market is highly competitive, with numerous companies vying for market share. The company's vertically integrated model and franchise strategy differentiate it from some competitors, but it also faces challenges from larger, well-capitalized players. The industry is subject to significant regulatory uncertainty, which can impact operations and profitability. The company's focus on the Arizona market provides a degree of geographic concentration, but also exposes it to state-specific regulatory risks.

Clientes Clave

  • Medical cannabis patients in Arizona.
  • Adult-use cannabis consumers in Arizona.
  • Entrepreneurs seeking to operate cannabis dispensaries through the Unity Rd franchise program.
Confianza de la IA: 71% Actualizado: 16 mar 2026

Finanzas

Gráfico e información

Precio de la acción de Item 9 Labs Corp. (INLB): Price data unavailable

Últimas noticias

Consenso de analistas

Calificación de Consenso

Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para INLB.

Objetivos de Precios

Análisis del precio objetivo de Wall Street para INLB.

MoonshotScore

45/100

¿Qué significa esta puntuación?

El MoonshotScore califica el potencial de crecimiento de INLB en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.

Liderazgo: Jeffrey I. Rassas

CEO

Jeffrey I. Rassas serves as the CEO of Item 9 Labs Corp. His background includes experience in managing and scaling businesses, though specific details on his prior roles and education are not available. He has been instrumental in guiding Item 9 Labs' growth strategy, focusing on vertical integration and franchise expansion. His leadership is focused on navigating the complex regulatory landscape of the cannabis industry and driving revenue growth.

Historial: Under Jeffrey I. Rassas's leadership, Item 9 Labs Corp. has expanded its dispensary network and franchise operations. He has overseen the development of new cannabis products and the implementation of strategic partnerships. His focus has been on building a sustainable and scalable business model in the rapidly evolving cannabis market. However, the company's path to profitability remains a key challenge.

Información del mercado OTC de INLB

OTC Other, also known as the Grey Market, represents the lowest tier of the OTC market. Companies in this tier often do not meet minimum financial standards and may not provide regular financial disclosures. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to exchanges like the NYSE or NASDAQ. These companies may be defunct, experiencing financial distress, or unwilling to adhere to higher reporting standards. Investors should exercise extreme caution and conduct thorough due diligence before considering an investment in an OTC Other company.

  • Nivel OTC: OTC Other
  • Estado de divulgación: Unknown
Liquidez: Liquidity for stocks on the OTC Other tier is typically very low. This can result in wide bid-ask spreads and difficulty in buying or selling shares without significantly impacting the price. The low trading volume increases the risk of price manipulation and makes it challenging to exit a position quickly. Investors should be prepared for potentially illiquid trading conditions.
Factores de riesgo OTC:
  • Limited financial disclosure
  • Low trading volume and liquidity
  • Potential for price manipulation
  • Higher risk of fraud or mismanagement
  • Lack of regulatory oversight
Lista de verificación de diligencia debida:
  • Verify the company's legal status and registration.
  • Obtain and review any available financial statements.
  • Assess the company's business model and competitive landscape.
  • Evaluate the management team's experience and track record.
  • Check for any legal or regulatory issues.
  • Understand the risks associated with the OTC Other tier.
  • Consult with a qualified financial advisor.
Señales de legitimidad:
  • Company's operational status (active vs. defunct)
  • Existence of a physical headquarters and operational facilities
  • Presence of a management team and employees
  • Any available news or press releases about the company
  • Information from third-party sources (if available)

Acciones de Item 9 Labs Corp.: Preguntas Clave Respondidas

¿Cuáles son los factores clave para evaluar INLB?

Item 9 Labs Corp. (INLB) actualmente tiene una puntuación IA de 45/100, indicando puntuación baja. Fortaleza clave: Vertically integrated operations. Riesgo principal a monitorear: Potential: Regulatory uncertainty and changes in cannabis laws.. Esto no es asesoramiento financiero.

¿Qué es el MoonshotScore de INLB?

INLB actualmente puntúa 45/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.

¿Con qué frecuencia se actualizan los datos de INLB?

Los precios de INLB se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.

¿Qué dicen los analistas sobre INLB?

La cobertura de analistas para INLB incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.

¿Cuáles son los riesgos de invertir en INLB?

Las categorías de riesgo para INLB incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Regulatory uncertainty and changes in cannabis laws.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.

¿Cuál es la relación P/E de INLB?

La relación P/E para INLB compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.

¿Está INLB sobrevalorada o infravalorada?

Determinar si Item 9 Labs Corp. (INLB) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.

¿Cuál es el rendimiento por dividendo de INLB?

Item 9 Labs Corp. (INLB) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.

Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.

Recursos Oficiales

Análisis actualizado el Puntuación de IA actualizada diariamente
Fuentes de Datos y Metodología
Datos de mercado proporcionados por Financial Modeling Prep y Yahoo Finance. Análisis de IA por algoritmos propietarios de Stock Expert AI. Indicadores técnicos mediante cálculos estándar de la industria. Última actualización: .

Datos proporcionados solo con fines informativos.

Notas de análisis
  • Financial data is limited due to the company's OTC listing and disclosure status.
  • Analyst coverage is not available for this stock.
Fuentes de datos

Popular Stocks